ANIMAL IMAGING CORE

动物成像核心

• 批准号: 7550459
• 负责人: JASON Arthur KOUTCHER
• 金额: $ 14.82万
• 依托单位: SLOAN-KETTERING INST CAN RESEARCH
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/7550459
• 关键词: Anatomy; Androgen Receptor; Animal Model; Animals; Ansamycin Antineoplastic Antibiotic; Antibodies; Area; Arts; Biological Assay; Biological Markers; Biological Testing; Biology; Bioluminescence; Biomedical Engineering; Biometry; Biopsy; Biopsy Specimen; British; Cancer Biology; Chemoprevention; Clinic; Clinical Research; Clinical Trials; Commit; Computers; Core Facility; DNA; DNA Vaccines; Development; Diagnostic; Discipline of Nuclear Medicine; Disease; Disseminated Malignant Neoplasm; Drug Delivery Systems; Environment; Equipment; Extraordinary Opportunities for Investment; Facility Construction Funding Category; Fluorescence; Funding; Future; Genetic; Glutamate Carboxypeptidase II; Goals; Grant; Green Fluorescent Proteins; Growth; Heart; Heat-Shock Proteins 90; Human; Idoxuridine; Image; Imaging Techniques; Imaging technology; Immunohistochemistry; Immunology; Immunotherapy; Institution; Interruption; Intervention; Invasive; Investigation; Laboratories; Local Therapy; Localized; Longitudinal Studies; Luc Gene; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Malignant Neoplasms; Malignant neoplasm of prostate; Measures; Medicine; Memorial Sloan-Kettering Cancer Center; Metastatic Prostate Cancer; Methionine; Methodology; Methods; Modality; Modeling; Molecular; Molecular Genetics; Monitor; Morbidity - disease rate; Mus; Neoplasm Metastasis; Non-Invasive Cancer Detection; Operative Surgical Procedures; Optical Methods; Optical Tomography; Optics; Organism; Pathologic; Pathologic Processes; Pathway interactions; Patient Care; Patient observation; Patients; Permeability; Personal Satisfaction; Pharmaceutical Preparations; Phase I Clinical Trials; Phenotype; Photons; Physicians; Physiologic pulse; Pilot Projects; Population; Positioning Attribute; Positron-Emission Tomography; Pre-Clinical Model; Principal Investigator; Procedures; Prostate; Prostatic Neoplasms; Pulse taking; Radionuclide Imaging; Range; Rate; Recruitment Activity; Relative (related person); Reproduction spores; Research; Research Infrastructure; Research Personnel; Research Project Grants; Resistance; Resolution; Rifabutin; Risk; Scientist; Screening procedure; Selection for Treatments; Small Animal Imaging Resource Programs; Staging; Structure; Superficial Lesion; Surgeon; System; TNFRSF5 gene; Temperature; Testing; Therapeutic Intervention; Tissue Microarray; Tracer; Translational Research; Vaccines; Validation; X-Ray Computed Tomography; antiangiogenesis therapy; base; bioimaging; cancer care; cancer diagnosis; cancer genetics; carcinogenesis; career; chemotherapy; cohort; cost; experience; fluorodeoxyglucose; human disease; image registration; improved; men; mortality; multidisciplinary; neoplastic; novel; novel diagnostics; novel therapeutics; optical imaging; outcome forecast; pre-clinical; preclinical study; predictive modeling; programs; radiofrequency; respiratory; response; single photon emission computed tomography; tomography; tool; translation assay; tumor; tumor growth; tumor molecular fingerprint; vaccine development

DESCRIPTION (provided by applicant): The MSKCC SPORE in Prostate Cancer, initially funded in 2001, focused on four broad translational research goals: (1) to develop better predictive models of prognosis for localized prostate cancer incorporating validated molecular markers to improve treatment selection; (2) to identify critical molecular and genetic mechanisms of prostate carcinogenesis, progression, and metastasis; (3) to develop PSMA- targeted DMA vaccines for men with rising PSA after local therapy; and (4) to develop new mechanism- based drugs for castrate-resistant metastatic cancers. With strong support from the SPORE and our institution, we have made considerable progress. We have completed a long-term study of watchful waiting in a large British cohort and have collected diagnostic biopsy specimens as tissue microarrays for marker analyses. We have created more than a dozen new animal models of prostate cancer that mimic the human disease, and identified and validated predictive molecular markers. We have documented the efficacy of a PSMA DNA vaccine in a phase 1 clinical trial. And we have demonstrated that Hsp90 targeted therapy with ansamycin degrades the androgen receptor and is active against castrate metastatic prostate cancer. We now have in place an experienced, productive multidisciplinary team of investigators committed to translational research in prostate cancer, a large patient population amenable to participation in clinical trials, and superb infrastructure to support such trials. With a large cadre of scientists exploring the biology of prostate cancer and developing new therapeutic strategies, we have a healthy pipeline of new ideas ripe for investigation as diagnostic and therapeutic interventions. In preparing our SPORE for the next cycle, we have retained the overall objectives and the four major research projects, which function as flexible, multidisciplinary programs where we are able to shift emphasis to the most promising areas of research within the framework of original goals as new information emerges. We have added one new project, Checkpoint Blockade in Immunotherapy of Prostate Cancer, by James Allison, recently recruited here as Chair of Immunology. We will retain five cores (Biospecimen, Biostatistics, Animal Models, Animal Imaging, and Administration) and discontinue the DNA Array Core, replaced by the MSKCC core facility. Career Development has successfully recruited four new translational investigators to our SPORE, and Developmental Research has funded ten pilots with over $1.8 million in additional institutional support, several of which have achieved independent funding. Our investigators collaborate successfully with other SPOREs in Prostate Cancer and institutions and they have been among the leaders in inter-SPORE clinical trials and the pilot National Biorepository Network. With continued support the MSKCC SPORE is well positioned to move novel diagnostic and therapeutic interventions rapidly from the laboratory to the human disease with the goal of reducing morbidity and mortality from prostate cancer.

描述（由申请人提供）：MSKCC SPORE in Prostate Cancer，最初于2001年获得资助，专注于四个广泛的转化研究目标：（1）开发更好的局部前列腺癌预后预测模型，纳入经验证的分子标志物，以改善治疗选择;（2）鉴定前列腺癌发生、进展和转移的关键分子和遗传机制;（3）为局部治疗后PSA升高的男性开发PSMA靶向DMA疫苗;以及（4）为去势抵抗性转移性癌症开发基于新机制的药物。在SPORE和我们机构的大力支持下，我们取得了长足的进步。我们已经完成了一项长期的观察等待在一个大的英国队列研究，并收集了诊断活检标本作为组织微阵列的标志物分析。我们已经创建了十几种新的前列腺癌动物模型，模拟人类疾病，并确定和验证预测分子标记。我们已经在1期临床试验中记录了PSMA DNA疫苗的有效性。我们已经证明，Hsp 90靶向治疗安莎霉素降解雄激素受体，并对去势转移性前列腺癌有效。我们现在有一个经验丰富，富有成效的多学科研究人员团队致力于前列腺癌的转化研究，大量的患者人群适合参与临床试验，以及支持此类试验的一流基础设施。随着大量科学家探索前列腺癌的生物学和开发新的治疗策略，我们有一个健康的管道，新的想法成熟的调查作为诊断和治疗干预措施。在为下一个周期准备我们的SPORE时，我们保留了总体目标和四个主要研究项目，这些项目作为灵活的多学科项目发挥作用，随着新信息的出现，我们能够在原始目标的框架内将重点转移到最有前途的研究领域。我们增加了一个新项目，前列腺癌免疫治疗中的检查点阻断，由詹姆斯·艾利森（James Allison）最近在这里招募为免疫学主席。我们将保留五个核心（生物标本、生物统计学、动物模型、动物成像和管理），并停止DNA阵列核心，由MSKCC核心机构取代。职业发展已经成功地为我们的SPORE招募了四名新的翻译研究人员，而发展研究已经为十名试点项目提供了超过180万美元的额外机构支持，其中一些已经获得了独立的资金。我们的研究人员与前列腺癌和机构的其他SPORE成功合作，他们一直是SPORE间临床试验和试点国家生物储存网络的领导者。在持续的支持下，MSKCC SPORE处于有利地位，可以将新的诊断和治疗干预措施迅速从实验室转移到人类疾病中，目标是降低前列腺癌的发病率和死亡率。